Ignite Creation Date:
2025-12-25 @ 12:18 AM
Ignite Modification Date:
2025-12-25 @ 10:21 PM
Study NCT ID:
NCT05037058
Status:
UNKNOWN
Last Update Posted:
2021-09-08
First Post:
2021-08-31
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
China Diabetes Cardiovascular Initiative
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D054058', 'term': 'Acute Coronary Syndrome'}, {'id': 'D003920', 'term': 'Diabetes Mellitus'}], 'ancestors': [{'id': 'D017202', 'term': 'Myocardial Ischemia'}, {'id': 'D006331', 'term': 'Heart Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'OTHER', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 9600}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2021-09-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-08', 'completionDateStruct': {'date': '2023-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-08-31', 'studyFirstSubmitDate': '2021-08-31', 'studyFirstSubmitQcDate': '2021-08-31', 'lastUpdatePostDateStruct': {'date': '2021-09-08', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-09-08', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-12-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Proportion of patients receiving dual antiplatelet therapy at arrival (within 24 hours)', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of STEMI patients receiving fibrinolytic therapy within 30 minutes after arrival among those receiving this treatment', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of STEMI patients receiving reperfusion therapy by PCI', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of STEMI patients receiving primary PCI within 90 minutes after arrival among those receiving this treatment', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of NSTE-ACS patients receiving early cardiac troponin measurement (within 6 hours of arrival)', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of NSTE-ACS patients receiving risk stratification at admission', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of NSTE-ACS patients receiving PCI within recommended times for patients with high or intermediate risk', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of patients prescribed dual antiplatelet medications at discharge', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of patients with indications prescribed a beta-blocker at discharge', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of patients prescribed a statin at discharge', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of patients with indications prescribed an ACE-I or ARB at discharge', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of patients that receiving an LDL-C assessment', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of patients with evaluation for LV systolic function by echocardiography', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of smoking patients that receiving smoking cessation advice/counseling', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of patients receiving fasting glucose test at least twice', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of patients receiving HbA1C test', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of patients prescribed a SGLT-2 inhibitor or a GLP-1 receptor agonist at discharge with cardiovascular disease benefit', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of patients with body height and weight measured and documented', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of patients receiving guidance on individualized dietary', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}, {'measure': 'Proportion of patients receiving guidance on individualized physical activity', 'timeFrame': 'Duration of hospital stay, an expected average of 1 week'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Acute Coronary Syndrome', 'Diabetes Mellitus']}, 'descriptionModule': {'briefSummary': 'As a collaborative project between American Heart Association, Chinese Society of Cardiology, American Diabetes Association and Chinese Diabetes Society, the China Diabetes Cardiovascular Initiative aims to enhance the attention and awareness of cardiovascular health care professionals (HCPs) in the managements of cardiovascular diseases and diabetes, to reduce diabetes-related complication and minimize adverse events in patients with cardiovascular disease, and to reduce the risk of cardiovascular morbidity and mortality in diabetic patients.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Patients hospitalized with acute coronary syndrome and diabetes from 40 tertiary hospitals from China.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Patients hospitalized with acute coronary syndrome and diabetes.\n2. Aged at least 18 years.\n\nExclusion Criteria:\n\nNone'}, 'identificationModule': {'nctId': 'NCT05037058', 'acronym': 'CDCV', 'briefTitle': 'China Diabetes Cardiovascular Initiative', 'organization': {'class': 'OTHER', 'fullName': 'Beijing Institute of Heart, Lung and Blood Vessel Diseases'}, 'officialTitle': 'China Diabetes Cardiovascular Initiative', 'orgStudyIdInfo': {'id': 'CDCV2021'}}, 'armsInterventionsModule': {'interventions': [{'name': 'Quality improvement activities', 'type': 'OTHER', 'description': 'Quality improvement activities'}]}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Yongchen Hao, Ph. D', 'role': 'CONTACT', 'email': 'haoyongchen123@163.com', 'phone': '+86(10)64456549'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Beijing Institute of Heart, Lung and Blood Vessel Diseases', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Professor of Beijing Institute of Heart, Lung and Blood Vessel Diseases', 'investigatorFullName': 'Dong ZHAO', 'investigatorAffiliation': 'Beijing Institute of Heart, Lung and Blood Vessel Diseases'}}}}